It is an eye-catching angle in the story of an experimental treatment for Ebola: An experimental treatment comes from tobacco plants that were turned into living pharmaceutical factories.
Using plants this way — sometimes called “pharming” — can produce complex and valuable proteins for medicines. That approach, studied for about 20 years, has not caught on widely in the pharmaceutical industry.
However, some companies and academic labs are pursuing it to create medicines and vaccines against such targets as HIV, cancer, the deadly Marburg virus and norovirus, known for causing outbreaks of stomach bugs on cruise ships, as well as Ebola.
Photo: Reuters
While most of the work in this area uses a tobacco plant, it is just a relative of the plant used to make cigarettes.
“It’s definitely not something you smoke,” said Jean-Luc Martre, a spokesman for Medicago, a Canadian company that is testing flu vaccines made with tobacco.
Medicago has a new production facility in Research Triangle Park, North Carolina. Once approved by federal authorities, it is expected to be able to make 30 million doses of seasonal flu vaccine a year, or 120 million vaccine doses to fight a major outbreak of “pandemic” flu, if the government requests it.
Scientists favor tobacco plants because they grow quickly and their biology is well-understood, said Ben Locwin, a pharmaceutical biotech consultant in Portsmouth, New Hampshire, who is considered an expert on plant-produced medicines by the American Association of Pharmaceutical Scientists.
The North Carolina operation can handle as many as 90,000 plants. Under fans, rows of young seedlings grow for about a month, until they are about 30cm tall. Then they are taken by robots to another section of the facility, turned upside down and dipped in a tank to be “infiltrated” with whatever proteins the researchers wish to grow.
There are a number of potential Ebola treatments and vaccines in development. One comes from tobacco plants grown in specialized greenhouses at another operation, Kentucky BioProcessing, in Owensboro, Kentucky.
That experimental treatment, called ZMapp, uses proteins called antibodies and is designed to inactivate the Ebola virus and help the body kill infected cells. It had not been tested in people, but showed promise in animal tests, so it was tried in three people sickened by Ebola in West Africa — two US aid workers, and a Spanish missionary priest who later died.
The last few doses available are in Liberia.
Kentucky BioProcessing, which produces it for the San Diego-based Mapp Biopharmaceutical, said it would take several months to make more, but it is working to increase production.
In general, the idea behind pharming is to slip the genetic blueprints for a particular protein into a plant and let the plant’s protein-making machinery go to work. Then the protein can be extracted from plant tissues. While tobacco plants are a mainstay of such work, proteins have also been produced in other plants, such as safflower and potato.
In fact, the only medicine made this way that the US government has approved for general use in people is made in a laboratory from cells of carrot plants. It treats a genetic illness called Gaucher’s disease. The drug was approved in 2012 by the US Food and Drug Administration (FDA).
A plant-made vaccine for a chicken disease gained approval from the US Department of Agriculture in 2006, but was never brought to market. Another plant-produced product to fight germs that cause tooth decay has been approved for use in Europe.
The lack of any stronger track record for approved drugs in the US is a key reason why the plant-based technology has not been embraced more fully, Locwin said.
That is despite it offering benefits like lower costs than the standard approach of using vats of cells from mammals to churn out complex proteins, Locwin said.
Some companies use cells from bacteria instead, but they cannot always produce the complicated proteins that drug companies need, he said.
The plant-based approach “has a tremendous amount of promise, but it doesn’t yet have the FDA blessing across the board to be able to say this is successful” and a proven way to get a drug to market, he said.
And it would cost companies money to change over to the new technology, he said.
However, plant-based drugs have attracted the attention and funding of the US government as a fast and cheap approach to make a lot of vaccine material in case of terrorist attacks, said Daniel Tuse, a consultant and managing director of Intrusept Biomedicine, which also works with tobacco plants in Owensboro.
If a new germ appears, genetic material from it can be quickly inserted into plants, and large numbers of the plants can churn out supplies of material for vaccines or treatments, he said.
The plant-based experimental Ebola treatment was developed with government support.
Nearly half of China’s major cities are suffering “moderate to severe” levels of subsidence, putting millions of people at risk of flooding, especially as sea levels rise, according to a study of nationwide satellite data released yesterday. The authors of the paper, published by the journal Science, found that 45 percent of China’s urban land was sinking faster than 3mm per year, with 16 percent at more than 10mm per year, driven not only by declining water tables, but also the sheer weight of the built environment. With China’s urban population already in excess of 900 million people, “even a small portion
UNSETTLING IMAGES: The scene took place in front of TV crews covering the Trump trial, with a CNN anchor calling it an ‘emotional and unbelievably disturbing moment’ A man who doused himself in an accelerant and set himself on fire outside the courthouse where former US president Donald Trump is on trial has died, police said yesterday. The New York City Police Department (NYPD) said the man was declared dead by staff at an area hospital. The man was in Collect Pond Park at about 1:30pm on Friday when he took out pamphlets espousing conspiracy theories, tossed them around, then doused himself in an accelerant and set himself on fire, officials and witnesses said. A large number of police officers were nearby when it happened. Some officers and bystanders rushed
Beijing is continuing to commit genocide and crimes against humanity against Uyghurs and other Muslim minorities in its western Xinjiang province, U.S. Secretary of State Antony Blinken said in a report published on Monday, ahead of his planned visit to China this week. The State Department’s annual human rights report, which documents abuses recorded all over the world during the previous calendar year, repeated language from previous years on the treatment of Muslims in Xinjiang, but the publication raises the issue ahead of delicate talks, including on the war in Ukraine and global trade, between the top U.S. diplomat and Chinese
HYPOCRISY? The Chinese Ministry of Foreign Affairs yesterday asked whether Biden was talking about China or the US when he used the word ‘xenophobic’ US President Joe Biden on Wednesday called for a hike in steel tariffs on China, accusing Beijing of cheating as he spoke at a campaign event in Pennsylvania. Biden accused China of xenophobia, too, in a speech to union members in Pittsburgh. “They’re not competing, they’re cheating. They’re cheating and we’ve seen the damage here in America,” Biden said. Chinese steel companies “don’t need to worry about making a profit because the Chinese government is subsidizing them so heavily,” he said. Biden said he had called for the US Trade Representative to triple the tariff rates for Chinese steel and aluminum if Beijing was